With Biocartis, he is today revolutionizing molecular diagnostics with a new generation of high precision diagnostic solutions in oncology and infectious diseases, easily accessible on a global scale, and as such enable better and faster access to new, more personalized treatments for patients. Mr. Pauwels is (co)-author or more than 150 papers in peer-reviewed journals and is the recipient of several awards for his scientific and entrepreneurial accomplishments. Mr. Pauwels holds a PhD in Pharmaceutical Sciences from the Katholieke Universiteit Leuven, Belgium.
Prior to joining Biocartis, Erwin held the position of Director Project Management at Ablynx N.V. (Gent, Belgium) from 2008-2010. He also gained extensive experience in in vitro diagnostics (IVD) development of molecular diagnostic assays during his 18 years at Innogenetics NV (Gent, Belgium), where he held various R&D management positions, including at the departments of infectious diseases, virology and microbiology. Erwin holds a PhD in Molecular Biology from the University of Ghent and an Executive MBA from the Vlerick Leuven-Gent Management School.
He has over 25 years of cross-cultural healthcare experience in Operational Excellence, with an outstanding track record of improving processes to excellence, extensive compliance knowledge (including Consent Decree), achieving superior business results and building competency and sustainable capabilities.
Reginald holds a Master Degree in Engineering from University of Brussels and is a certified Master Black Belt in Lean and Black Belt in Six Sigma.
Erik has a proven track record in the development of molecular diagnostic platforms. Before joining Biocartis, he worked at Philips where he headed the molecular diagnostic assay development team, and afterwards became responsible for Business Development and Technology Strategy for Philips’ Molecular Diagnostics Business Unit. Erik had a pivotal role in the development of Philips Molecular Diagnostics platform, which was acquired by Biocartis in 2010.
Erik obtained his Master’s degree in Chemistry from the Radboud University Nijmegen (1999). In 2004 he obtained his PhD at the department of Autoimmune Biochemistry at the same university.
Geert started his career at Innogenetics in 1990, where he initiated the hepatitis-C program. He was head of the company’s Infectious Diseases Business Unit, which developed and marketed >20 diagnostic assays for HIV, HBV, HCV and bacterial typing and resistance during his tenure. Geert was put in charge of HBV, HCV, and HPV vaccine and mAb development in 2002. With the incorporation of GENimmune as a therapeutic vaccines specialty subsidiary of Innogenetics in September 2007, he became Vice President Corporate Development, a post he held until 2008.
Geert holds a Master's in Biology from the University of Gent (1984). He continued his studies with Prof. Walter Fiers, working on engineered recombinant hemagglutinin vaccines for universal protection against influenza, and obtained his PhD in 1989. Geert frequently lectures at international meetings, and is an inventor with more than 20 HCV and HBV patent families. He is a reviewer for several scientific journals, evaluates project applications for several European agencies, and has (co-)authored over 85 peer reviewed papers.
Eric trained in internal medicine and gastroenterology as well as specialized in GI oncology at KU Leuven. He has a large clinical practice in Leuven and leads or is involved in many national and international clinical and translational research projects on gastrointestinal cancer. He holds an MD and a PhD from KU Leuven.
He has published more than 340 peer-reviewed articles (on pubmed; H-factor: 70; >20000 citations – January 2013) in prestigious journals such as the New England Journal of Medicine, the Journal of Clinical Oncology and The Lancet. He is co-editor of the reference textbook on gastrointestinal cancer Principles and Practice of Gastrointestinal Oncology (Second edition, 2008), and is/has been an editorial board member of numerous leading journals, including the Journal of Clinical Oncology, Annals of Oncology, and European Journal of Cancer. He is Associate Editor of Targeted Oncology and Editor of European Journal Cancer since January 2011.
Eric is a member of several scientific organizations. He is/was a member of the Scientific Program Committee and/or Educational Committee of ASCO, ASCO-GI Cancers Symposium, ESMO and ECCO. He is also a member of the ESMO faculty and joined the ESMO Executive Board on July 1, 2011. He served as Secretary of the European Organisation for Research and Treatment of Cancer – Gastrointestinal Cancer (EORTC-GI) Group from 2000-2003, and as Chair from 2003-2007. He is Chairman of PETACC (Pan-European Trials on Adjuvant Colon Cancer) since 2008, Board member of EORTC since 2009, President of the European Society of Digestive Oncology (ESDO) and Co-chair of the European Neuro-Endocrine Tumour Society (ENETS) Registry. He also chairs the colon cancer prevention task force of the Flemish government (B) and is President of BGDO (Belgian Group Digestive Oncology) and FAPA (Familial Adenomatous Polyposis Association). Eric Van Cutsem is the founder and Chair of the Scientific Committee of the World Congress on Gastrointestinal Cancer in Barcelona (in partnership with ESMO) since 2005.
Josep holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is very actively involved in translational research and pharmacodynamic Phase I studies with molecular targeted therapies. He is especially devoted to Phase I and II pharmacodynamic endpoint studies with novel agents that target membrane receptors, including the EGFR family and IGF-1R, the PI3K and ERK signaling pathways, as well as downstream cytoplasmic and intra-nucleus effectors such as Mdm2/p53 and aurora kinase.
On the hypothesis that each tumor has an independent genetic identity, his research group very actively participates in the development of molecular therapies that target specific oncoproteins, with the purpose of developing personalized therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR, IGF1-R, etc.) for patients displaying genetic lesions or pathway dysregulation. One of the main objectives of the group is to identify new predictive markers of response to diverse treatments as well as markers of primary resistance (de novo) and secondary treatment. At the preclinical level, his research group is developing new xenograft models with explant tumors from patients ('xenopatients') in mice in order to mimic the patient’s disease and study tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).
Joseph is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). He also is a member of different Editorial Boards, including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer and Annals of Oncology. He has (co)authored approximately 250 peer-reviewed papers. He is/has been on the Educational and Scientific Committees of ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO and WCGIC meetings.
Alberto and his laboratory at the Institute for Cancer Research and Treatment (IRCC) in Turin (IT) have pioneered the generation of human X-MAN™ cell lines harboring subtle kinase mutations that make it possible to accurately predict responses to appropriately targeted agents in patients.
Recently, Prof. Bardelli and colleagues discovered that KRAS mutations impart secondary resistance to anti-EGFR therapies in colon cancer and that the mutations can be detected non-invasively in the blood of patients months before progression of the cancer can be measured by radiographic approaches. A future focus of his lab is to find appropriately tailored drug combinations to overcome acquired resistance to targeted therapies.
A future focus of his lab is to define other resistance mechanisms in patients and find appropriately tailored drug combinations that target them.
Patrick holds a medical degree (1985) from the University of Leuven (Belgium), where he also received his training in surgical pathology following a two-year residency in internal medicine. After working many years at the Stichting PAMM, Eindhoven (NL), he joined the Pathology Department of Maastricht University Hospital (NL). He also holds a PhD in Medical Sciences from the University of Leiden (NL).
After four years on the staff of Ghent University Hospital (Belgium), he moved to Antwerp. He is Co-director of CORE (Center for Oncology Research, Antwerp University). Professor Pauwels has done extensive research in the field of pathology, particularly in the molecular pathology of cancer, and is the author and co-author of some 100 peer-reviewed papers on this topic. His lab, as a central pathology reference lab, is involved in several trials. Recently, it screened some 4,000 lung cancers for ALK gene rearrangement using FISH tests.
His main research interests include the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents.
Dr. Press is the director of a reference laboratory (USC Breast Cancer Analysis Laboratory) engaged in private practice pathology on a referral basis (1988-present). In this laboratory he evaluates prognostic markers and predictive markers as well as histopathology used in making treatment decisions for women with breast cancer. He is the director of the central laboratory for the Cancer International Research Group (CIRG), a clinical trials organization that evaluates new therapies in predominantly breast cancer patients but also conducts trials in several other cancers including gastric cancer.
His particular area of research interest is in molecular alterations of breast and gynaecologic cancers, especially those that have the potential to be important in either diagnostic or therapeutic decision-making for patient management. The most prominent area of activity for his laboratory has been in the study of the human epidermal growth factor receptor type 2 (HER-2) in breast and other cancers. He published his first paper in this area in 1989 (Science 244: 707-712, 1989) and his laboratory is still actively contributing to this area as well as to the conduct of clinical trials evaluating HER-2 as a target for therapy.He is active in teaching medical students, graduate students, postdoctoral fellows and resident physicians.As the Co-Leader of the Women's Cancers Program at the USC Norris Cancer Center, he is responsible for coordinating research activities of basic scientists, clinical scientists, prevention scientists and epidemiologists and for presenting progress in competing renewal grant proposals for our NCI-funded Comprehensive Cancer Center.
Dr. Vincent is Professor of intensive care at University of Brussels, and intensivist in the Department of Intensive Care at the Erasme University Hospital in Brussels. Specialist in Internal Medicine, he spent two years of training at the University of Southern California with Prof. Max Harry Weil.
Dr. Vincent has signed more than 800 original articles, some 300 book chapters and review articles, and 850 original abstracts, and has edited 86 books. He is co-editor of the Textbook of Critical Care (Elsevier Saunders, 7th Edition) and the “Encyclopedia of Intensive Care Medicine” (Springer).
Dr. Vincent is the editor-in-chief of "Critical Care", "Current Opinion in Critical Care", and "ICU Management". He is member of the Editorial Boards of about 30 journals including "Critical Care Medicine" (senior editor), American Journal of Respiratory and Critical Care Medicine (AJRCCM), "PLoS Medicine", "Lancet Infectious Diseases", "Intensive Care Medicine", "Shock", and "Journal of Critical Care".
Dr. Vincent is President of the World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM). He is a Past-President of the Belgian Society of Intensive Care Medicine (SIZ), the European Society of Intensive Care Medicine (ESICM), the European Shock Society (ESS), and the International Sepsis Forum (ISF). He is member of the Royal Medical Academy of Belgium.
For 34 years he has organized an International Symposium on Intensive Care and Emergency Medicine which is held every March in Brussels.
He has received the Distinguished Investigator Award of the Society of Critical Care Medicine, the College Medalist Award of the American College of Chest Physicians, was the Recipient of the "Society Medal”(lifetime award) of the European Society of Intensive Care Medicine and has received the prestigious Belgian scientific award of the FRS-FNRS (Prix Scientifique Joseph Maisin-Sciences biomédicales cliniques).
After returning to the Netherlands (1989), he became a research associate in medical microbiology at the Diagnostic Medical Center (Delft), but moved back to clinical virology as a senior research associate in 1991 at the University Medical Center Rotterdam (Head Prof.dr. Ab Osterhaus). From 1993 till 2007, he was responsible for the molecular diagnostics unit. During this period, he has been involved in the discovery and characterization of several new viruses and variants. In 2007, he became professor and director of the new laboratory of Clinical Virology within the Department of Medical Microbiology at the University Medical Centre Groningen.
He has been actively involved in the implementation and development of new technologies like real-time amplification and automation within clinical virology. He has been focusing of molecular diagnostics and its use in a transplant setting as well in monitoring treatment of hepatitis viruses.
He is active as a board member in several national and international societies . Since 2000, he is scientific advisor and executive member within QCMD (Quality Control of Molecular Diagnostics). He is also an auditor for the Council of Accreditation. Furthermore, he is an executive member of the Dutch Society of Medical Microbiology and Editor-in-Chief of the Journal of Clinical Virology.